Imunon, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $500,000 | $500,000 |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M | -$21.0M |
| Operating expenses | $14.7M | $19.1M | $21.0M | $25.4M | $21.5M |
| Cash from operations | -$13.9M | -$18.9M | -$19.0M | -$23.1M | -$16.2M |
| Capital expenditure | $280,572 | $29,541 | $451,759 | $267,800 | $311,613 |
| Free cash flow | -$14.2M | -$18.9M | -$19.5M | -$23.4M | -$16.5M |
| Impairments | — | — | — | $13.4M | — |
| Total assets | $12.3M | $9.7M | $21.9M | $44.0M | $74.0M |
| Total liabilities | $5.2M | $5.5M | $8.5M | $14.6M | $18.3M |
| Total debt | — | — | — | $6.0M | — |
Shares outstanding 4.2M · Free float 31.9%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.